Navigation Links
Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
Date:1/24/2013

KANSAS CITY, Kan. and NEW YORK, Jan. 24, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced the appointment of Erick Lucera as Vice President of Corporate Development.  Mr. Lucera will leverage his broad experience managing investments in healthcare, as well as his network of industry contacts to facilitate business development and investment initiatives for Aratana.

Steven St. Peter , M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "Erick is well known in the healthcare industry and we are very excited to add him to our team.  His deep understanding of corporate strategy and proven ability to recognize and invest strategically in strong growth opportunities will be paramount to keeping Aratana on its current trajectory."

Mr. Lucera stated, "Aratana represents one of the most attractive investment models I've seen in my 15 years as a healthcare investor.  I am confident the human health industry is beginning to recognize the strategic importance and remarkable value in developing animal health strategies for their assets.  As part of my commitment to positioning Aratana as the partner of choice for these companies, I look forward to bringing in high-quality assets and delivering significant value through successful execution on our business initiatives."

Erick Lucera
Mr. Lucera has more than 15 years of diverse experience in the healthcare public equity markets.  Prior to joining Aratana, Mr. Lucera spent four years as Vice President and Healthcare Analyst at Eaton Vance Investment Managers.  From 2004 to 2007, Mr. Lucera was a Portfolio Manager at Intrepid Capital, where he successfully constructed and managed a portfolio constructed across biotech, pharmaceutical, device, and service companies.  Prior to that, Mr. Lucera held various leadership positions at Independence Investments, including Head of Healthcare Research.  Mr. Lucera began his career as a staff auditor and accountant at PwC.  He holds a CPH in public health from Harvard University, and M.S.F. in quantitative finance from The Wallace E. Carroll Graduate School of Management of Boston College, an MBA from Indiana University Bloomington and a B.S. in accounting from Lerner College of Business and Economics of University of Delaware.

About Aratana Therapeutics
Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals).  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market.  For more information, please visit www.aratanatherapeutics.com.

For Investors & Media:
Joshua Drumm , Ph.D. / Andrew Mielach
Tiberend Strategic Advisors, Inc.
(212) 827-0020  
jdrumm@tiberend.com   
amielach@tiberend.com


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
2. Aratana to Participate in Leerink Swanns November Management Access Days
3. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
4. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
5. PrimeMail, Prime Therapeutics mail-service pharmacy, receives URAC Reaccreditation
6. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
7. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
8. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
9. Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics
10. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
11. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Research and Markets has announced the addition of the "Dry ... offering. ... Dry eye Drugs Price Analysis and Strategies - 2016, provides drug pricing ... answers the following questions: What are the ... they positioned in the Global Dry eye market? What ...
(Date:2/24/2017)... CUPERTINO, Calif. , Feb. 24, 2017  In ... fourth quarter 2016 financial results press release, you are ... be broadcast live over the internet on Tuesday, March ... Pacific Time). A live audio webcast of ... at www.durect.com and clicking "Investor Relations."  If ...
(Date:2/24/2017)... NEW YORK , Feb. 24, 2017 ... Monteverde & Associates PC , a boutique securities ... New York City , announces that a ... of Massachusetts  against Inotek Pharmaceuticals ... purchasers of the Company,s securities between July 23, 2015 and ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... disabilities, it is so critically important that we all are aware of our ... why Mediaplanet is proud to announce the launch of its newest edition of ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... With ProGlass ... Cut Pro X . Users have total control over position, rotation, distortion, edge softness, ... all within Final Cut Pro X. , With ProGlass Prism users are given the ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... services, which specializes in thought leadership , media relations, social media, content ... services that will be powered through Act-On, an intuitive marketing automation platform. , ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an official 2017 partnership with The Jensie Gran Fondo of Marin. For the ... UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide ...
Breaking Medicine News(10 mins):